This merger aligns science, technology, clinics, and patients to help ensure the best fertility outcome.
New York, New York (PRWEB) March 12, 2015
Auxogyn, Inc. and Fertility Authority, LLC today announced the merger of the two companies. The combined company will be the first to provide fertility patients with easy accessibility to high quality doctors, price transparency and financing, extraordinary clinical expertise, and proprietary clinical solutions under one roof.
By leveraging Fertility Authority’s online patient-matching platform, the combined entity will enable more consumers to become educated about the benefits of single embryo transfer and about Auxogyn’s Eeva™ Test. The Eeva™ Test is a first-in-class FDA cleared non-invasive prognostic test that uses time-lapse imaging and statistical modeling to consistently and objectively assess early embryo development milestones with minimal disturbance to the embryos during incubation. The proprietary, automated Eeva Test helps IVF clinicians optimize their treatment for patients undergoing IVF procedures. Auxogyn received a CE mark for the Eeva™ Test in July 2012 and FDA clearance in June 2014.
The Company is privately held and funded by Kleiner Perkins Caufield & Byers (KPCB), TPG Biotech, SR One, and Merck Serono Ventures. The Company’s headquarters will be located in New York, NY with operations in Menlo Park, CA. Gina Bartasi is the company’s Chief Executive Officer and Darrin Uecker is the President and Chief Operating Officer.
“The holistic approach that our new combined company is able to offer patients represents a significant advancement in the end-to-end experience of fertility treatment and requires a talented management team,” said Dr. Beth Seidenberg, general partner at KPCB. “Gina, who has created the largest online marketplace for families seeking fertility solutions, together with Darrin, a seasoned technology development executive with decades of experience building proprietary medical technology, have both the passionate resolve and complementary skills necessary to ensure that we and patients achieve results.”
Gina Bartasi, Chief Executive Officer, added: “The patient is at the center of everything we do. This merger aligns science, technology, clinics, and patients to help ensure the best fertility outcome. We will deliver a comprehensive solution, from introducing patients to a high quality physician to the clinical care journey.”
“In March 2014, Auxogyn formed a strategic partnership with Merck Serono in the development and commercialization of the Eeva™ Test. Merck Serono has been instrumental in our ability to successfully commercialize the Eeva™ Test in the EU and Canada and with this merger we will be able to leverage the world’s largest patient-matching platform to expand rapidly here in the U.S. as well,” said Darrin Uecker, President and Chief Operating Officer.
About The Company:
We are the first company to provide fertility patients with easy accessibility to high quality doctors, price transparency, and financing, coupled with extraordinary clinical expertise and proprietary clinical solutions. The company is committed to helping ensure that patients control their fertility journey and achieve the best possible outcome. It does this by aligning science, technology, clinics, and patients through a unique portfolio of solutions, including: The Eeva™ Test, a non-invasive prognostic test developed to consistently and objectively assess early embryo development milestones; FertilityAuthority.com, the country’s leading patient-matching technology platform serving the fertility industry; EggBanxx.com, a national network of over 185 top fertility doctors specializing in egg freezing; and IVFAdvantage.com, the only multi-cycle IVF savings program created by patients for patients. The company is privately held and funded by Kleiner Perkins Caufield & Byers, TPG Biotech, SR One, and Merck Serono Ventures.